Key Pharmacologic Principles and Drug-Drug Interactions in HIV Patient Care
Summary
- Raltegravir is not affected by inhibitors or inducers of CYP 450 enzymes
- Atazanavir increases concentrations of raltegravir, although no dose adjustments are recommended with this combination for either approved raltegravir dosage (400 mg twice daily or 1200 mg once daily)[Iwamoto 2008; FDA Raltegravir]
- Efavirenz, etravirine, ritonavir, maraviroc, and tipranavir/ritonavir have demonstrated nonclinically significant decreases in raltegravir concentrations[Iwamoto 2008; Hanley 2009; Andrews 2010]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Drug-Drug Interactions, Pharmacokinetics